ATE390134T1 - (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen - Google Patents
(+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungenInfo
- Publication number
- ATE390134T1 ATE390134T1 AT01939312T AT01939312T ATE390134T1 AT E390134 T1 ATE390134 T1 AT E390134T1 AT 01939312 T AT01939312 T AT 01939312T AT 01939312 T AT01939312 T AT 01939312T AT E390134 T1 ATE390134 T1 AT E390134T1
- Authority
- AT
- Austria
- Prior art keywords
- piperidinemethanol
- dimethoxyphenyl
- prodrug
- fluorophenyl
- alpha
- Prior art date
Links
- 206010012289 Dementia Diseases 0.000 title 1
- 208000010877 cognitive disease Diseases 0.000 title 1
- 229940002612 prodrug Drugs 0.000 title 1
- 239000000651 prodrug Substances 0.000 title 1
- HXTGXYRHXAGCFP-UHFFFAOYSA-N volinanserin Chemical compound COC1=CC=CC(C(O)C2CCN(CCC=3C=CC(F)=CC=3)CC2)=C1OC HXTGXYRHXAGCFP-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US20694300P | 2000-05-25 | 2000-05-25 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE390134T1 true ATE390134T1 (de) | 2008-04-15 |
Family
ID=22768607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01939312T ATE390134T1 (de) | 2000-05-25 | 2001-05-23 | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4- fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20020099076A1 (de) |
| EP (1) | EP1289527B1 (de) |
| JP (1) | JP2003535058A (de) |
| KR (1) | KR100784655B1 (de) |
| CN (1) | CN1436078A (de) |
| AR (1) | AR029666A1 (de) |
| AT (1) | ATE390134T1 (de) |
| AU (2) | AU6484201A (de) |
| BR (1) | BR0111102A (de) |
| CA (1) | CA2410554C (de) |
| DE (1) | DE60133385T2 (de) |
| DK (1) | DK1289527T3 (de) |
| ES (1) | ES2300333T3 (de) |
| IL (1) | IL152908A0 (de) |
| MX (1) | MXPA02011511A (de) |
| NO (1) | NO20025630L (de) |
| NZ (1) | NZ522659A (de) |
| PT (1) | PT1289527E (de) |
| TW (1) | TWI299001B (de) |
| WO (1) | WO2001089498A2 (de) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK1534391T3 (da) | 2002-07-19 | 2007-06-11 | Biovitrum Ab | Nye piperazinyl-pyrazinonderivater til behandling af 5-HT2A-recptor-relaterede forstyrrelser |
| US7713954B2 (en) | 2004-09-30 | 2010-05-11 | Roche Palo Alto Llc | Compositions and methods for treating cognitive disorders |
| EP1799306B1 (de) * | 2004-09-30 | 2011-02-23 | F. Hoffmann-La Roche AG | Zusammensetzungen und verfahren zur behandlung kognitiver störungen |
| DE102006040278A1 (de) * | 2006-08-21 | 2008-03-20 | Technische Universität Dresden | Arzneimittel zur Behandlung des Charles-Bonnet-Syndroms |
| CN107848972B (zh) | 2015-07-20 | 2021-06-18 | 阿卡蒂亚药品公司 | 用于制备n-(4-氟苄基)-n-(1-甲基哌啶-4-基)-n’-(4-(2-甲基丙氧基)苯基甲基)脲及其酒石酸盐和多晶型c的方法 |
| US10953000B2 (en) | 2016-03-25 | 2021-03-23 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome P450 modulators |
| WO2017165635A1 (en) | 2016-03-25 | 2017-09-28 | Acadia Pharmaceuticals Inc. | Combination of pimavanserin and cytochrome p450 modulators |
| EP3436010B1 (de) * | 2016-03-29 | 2021-03-10 | Acadia Pharmaceuticals Inc. | Inverse 5-ht2a-serotonin-rezeptor-agonisten oder -antagonisten zur verwendung in der verringerung von amyloid-beta-peptiden und in der verringerung der akkumulation von amyloid-plaques |
| EP3558311A1 (de) | 2016-12-20 | 2019-10-30 | Acadia Pharmaceuticals Inc. | Pimavanserin allein oder in kombination zur verwendung in der behandlung von morbus-alzheimer-psychose |
| WO2018200977A1 (en) | 2017-04-28 | 2018-11-01 | Acadia Pharmaceuticals Inc. | Pimavanserin for treating impulse control disorder |
| WO2019046167A1 (en) | 2017-08-30 | 2019-03-07 | Acadia Pharmaceuticals Inc. | PIMAVANSERIN FORMULATIONS |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5169096A (en) * | 1985-07-02 | 1992-12-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl-piperidine-methanol derivatives |
| US4912117A (en) | 1985-07-02 | 1990-03-27 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds |
| US5021428A (en) | 1985-07-02 | 1991-06-04 | Merrell Dow Pharmaceuticals Inc. | Novel chemical compounds for the prophylactic treatment of migraine |
| US4783471A (en) | 1985-07-02 | 1988-11-08 | Merrell Dow Pharmaceuticals Inc. | N-aralkyl piperidine methanol derivatives and the uses thereof |
| US4877798A (en) | 1987-11-23 | 1989-10-31 | Merrell Dow Pharmaceuticals Inc. | Treatment of fibromyalgia |
| ATE102482T1 (de) | 1988-01-21 | 1994-03-15 | Merrell Dow Pharma | Verwendung von 1,4-disubstituierten-piperidinyl- verbindungen zur herstellung eines arzneimittels zur behandlung von schlaflosigkeit. |
| US5106855A (en) | 1989-12-20 | 1992-04-21 | Merrell Dow Pharmaceuticals Inc. | Method for the treatment of glaucoma |
| US6004980A (en) | 1990-06-01 | 1999-12-21 | Merrell Pharmaceuticals, Inc. | (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol |
| WO1991018602A1 (en) | 1990-06-01 | 1991-12-12 | Merrell Dow Pharmaceuticals Inc. | (+)-α-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL |
| US5618824A (en) * | 1994-03-09 | 1997-04-08 | Merrell Pharmaceuticals Inc. | Treatment of obsessive-compulsive disorders with 5-HT2 antagonists |
| FR2738819B1 (fr) * | 1995-09-14 | 1997-12-05 | Sanofi Sa | Nouveaux composes antagonistes selectifs du recepteur nk3 humain, procede pour leur obtention et compositions pharmaceutiques les contenant |
| EP0796619A1 (de) * | 1996-03-21 | 1997-09-24 | Merrell Pharmaceuticals Inc. | Verwendung von (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-Fluorophenyl)ethyl)-4-Piperidinmethanol zur Behandlung von Depressionen und bipolaren Erkrankungen |
| US6028083A (en) * | 1997-07-25 | 2000-02-22 | Hoechst Marion Roussel, Inc. | Esters of (+)-α-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl) ethyl]-4-piperidinemethanol |
| AU1118099A (en) * | 1997-10-23 | 1999-05-10 | Research Foundation Of The State University Of New York, The | Methods of screening potential atypical antipsychotic drugs |
| HRP20010140A2 (en) | 1998-08-28 | 2002-02-28 | Aventis Pharma Inc | THE USE OF R(+)-<F128M>a<F255D>-(2,3-DIMETHOXYPHENYL)-1-[2-(4-FLUOROPHENYL)ETHYL]-4-PIPERIDINEMETHANOL FOR THE TREATMENT OF SLEEP DISORDERS |
| UA57859C2 (uk) * | 1998-10-14 | 2003-07-15 | Авентіс Фармасьютікалз Інк. | СКЛАДНІ ЕФІРИ (+)-АЛЬФА-(2,3-ДИМЕТОКСИФЕНІЛ)-1-[2-(4-ФТОРФЕНІЛ)ЕТИЛ]-4-ПІПЕРИДИНМЕТАНОЛУ, СПОСІБ ЇХ ОТРИМАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ, СПОСІБ ІНГІБУВАННЯ ДІЇ СЕРОТОНІНУ НА 5HT<sub>2A</sub> РЕЦЕПТОР, СПОСІБ ЛІКУВАННЯ |
| US6455526B1 (en) * | 1998-12-16 | 2002-09-24 | Aventis Pharmaceuticals, Inc. | Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same |
-
2001
- 2001-05-18 US US09/861,980 patent/US20020099076A1/en not_active Abandoned
- 2001-05-23 EP EP01939312A patent/EP1289527B1/de not_active Expired - Lifetime
- 2001-05-23 AU AU6484201A patent/AU6484201A/xx active Pending
- 2001-05-23 KR KR1020027015968A patent/KR100784655B1/ko not_active Expired - Fee Related
- 2001-05-23 DK DK01939312T patent/DK1289527T3/da active
- 2001-05-23 TW TW090112318A patent/TWI299001B/zh not_active IP Right Cessation
- 2001-05-23 ES ES01939312T patent/ES2300333T3/es not_active Expired - Lifetime
- 2001-05-23 CA CA002410554A patent/CA2410554C/en not_active Expired - Fee Related
- 2001-05-23 AR ARP010102464A patent/AR029666A1/es unknown
- 2001-05-23 PT PT01939312T patent/PT1289527E/pt unknown
- 2001-05-23 AT AT01939312T patent/ATE390134T1/de not_active IP Right Cessation
- 2001-05-23 IL IL15290801A patent/IL152908A0/xx unknown
- 2001-05-23 CN CN01810983A patent/CN1436078A/zh active Pending
- 2001-05-23 AU AU2001264842A patent/AU2001264842B2/en not_active Ceased
- 2001-05-23 MX MXPA02011511A patent/MXPA02011511A/es active IP Right Grant
- 2001-05-23 DE DE60133385T patent/DE60133385T2/de not_active Expired - Fee Related
- 2001-05-23 WO PCT/US2001/016653 patent/WO2001089498A2/en not_active Ceased
- 2001-05-23 NZ NZ522659A patent/NZ522659A/en unknown
- 2001-05-23 BR BR0111102-7A patent/BR0111102A/pt not_active Application Discontinuation
- 2001-05-23 JP JP2001585743A patent/JP2003535058A/ja active Pending
-
2002
- 2002-08-13 US US10/217,843 patent/US20030036553A1/en not_active Abandoned
- 2002-11-22 NO NO20025630A patent/NO20025630L/no not_active Application Discontinuation
-
2004
- 2004-05-03 US US10/838,035 patent/US7132433B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2001089498A2 (en) | 2001-11-29 |
| IL152908A0 (en) | 2003-06-24 |
| CA2410554C (en) | 2009-02-03 |
| KR100784655B1 (ko) | 2007-12-12 |
| AU6484201A (en) | 2001-12-03 |
| MXPA02011511A (es) | 2003-04-25 |
| DE60133385T2 (de) | 2009-04-23 |
| PT1289527E (pt) | 2008-05-13 |
| NO20025630L (no) | 2003-01-24 |
| CN1436078A (zh) | 2003-08-13 |
| DK1289527T3 (da) | 2008-07-14 |
| PL359176A1 (en) | 2004-08-23 |
| JP2003535058A (ja) | 2003-11-25 |
| TWI299001B (en) | 2008-07-21 |
| US20040204457A1 (en) | 2004-10-14 |
| NO20025630D0 (no) | 2002-11-22 |
| WO2001089498A3 (en) | 2002-05-10 |
| AR029666A1 (es) | 2003-07-10 |
| DE60133385D1 (de) | 2008-05-08 |
| EP1289527B1 (de) | 2008-03-26 |
| KR20030034078A (ko) | 2003-05-01 |
| CA2410554A1 (en) | 2001-11-29 |
| NZ522659A (en) | 2004-06-25 |
| US7132433B2 (en) | 2006-11-07 |
| AU2001264842B2 (en) | 2005-01-27 |
| EP1289527A2 (de) | 2003-03-12 |
| ES2300333T3 (es) | 2008-06-16 |
| BR0111102A (pt) | 2003-03-11 |
| US20020099076A1 (en) | 2002-07-25 |
| US20030036553A1 (en) | 2003-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE250605T1 (de) | Piperidin verbindung zur behandlung von psoriasis | |
| DE60132777D1 (de) | Benzothiazolderivate zur behandlung von alzheimer und parkinson | |
| DE60234760D1 (de) | Phenylindole zur behandlung von hiv | |
| DE60219292D1 (de) | Pyrazolderivate zur behandlung von hiv | |
| DE60208221D1 (de) | Heterozyklische verbindungen zur behandlung von harnwegserkrankungen | |
| DE60019556D1 (de) | 2-amino-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE69910368D1 (de) | Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen | |
| DE60019555D1 (de) | 2-oxy-benzoxazinonderivate zur behandlung von fettleibigkeit | |
| DE60124302D1 (de) | Thiazolderivate zur behandlung von ppar-lierte krankheiten | |
| NO20014047L (no) | Monoamin reopptaksinhibitorer for behandling av CNS forstyrrelser | |
| DE602004020072D1 (de) | 1,2,3,4-tetrasubstituiertes indol zur behandlung von atemwegserkrankungen | |
| DE69934877D1 (de) | Biochanin-angereicherter extrakt zur behandlung von estrogenabhängigen erkrankungen | |
| NO20034311D0 (no) | CCR5-antagonister for behandling av AIDS | |
| ATE297917T1 (de) | 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen | |
| DE60136477D1 (de) | Retinoide zur behandlung von emphysem | |
| ATE357438T1 (de) | 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems | |
| DE602004003952D1 (de) | Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders | |
| DE60130365D1 (de) | Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen. | |
| ATE369130T1 (de) | Carbamatverbindungen zur vorbeugung und behandlung von bewegungsstörungen | |
| DE60133385D1 (de) | (+)-alpha-(2,3-dimethoxyphenyl)-1-(2-(4-fluorophenyl)ethyl)-4-piperidinemethanol oder prodrug davon zur behandlung von demenzsymptomen oder kognitiven störungen | |
| DE60238765D1 (de) | Carbamatverbindungen zur behandlung von schmerz | |
| ID27214A (id) | Triazolopiridina untuk pengobatan gangguan trombosis | |
| DE50105735D1 (de) | Chlorzoxazon zur behandlung von psoriasis | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| ATE312104T1 (de) | Verbindungen zur behandlung von beeinträchtigten fundischen entspannung |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1289527 Country of ref document: EP |
|
| REN | Ceased due to non-payment of the annual fee |